Argentarii LLC Acquires New Shares in Bristol-Myers Squibb (NYSE:BMY)

Argentarii LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,394 shares of the biopharmaceutical company’s stock, valued at approximately $249,000.

Several other large investors have also bought and sold shares of the business. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $45,000. Kendall Capital Management boosted its stake in shares of Bristol-Myers Squibb by 6.7% during the fourth quarter. Kendall Capital Management now owns 47,632 shares of the biopharmaceutical company’s stock valued at $2,694,000 after purchasing an additional 2,985 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in shares of Bristol-Myers Squibb by 68.1% during the fourth quarter. Personal CFO Solutions LLC now owns 37,972 shares of the biopharmaceutical company’s stock valued at $2,148,000 after purchasing an additional 15,389 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in shares of Bristol-Myers Squibb by 6.8% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,288 shares of the biopharmaceutical company’s stock valued at $1,996,000 after purchasing an additional 2,247 shares in the last quarter. Finally, Rialto Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $84,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 1.6 %

Shares of NYSE:BMY opened at $61.16 on Monday. The stock has a market cap of $124.11 billion, a price-to-earnings ratio of -13.84, a PEG ratio of 2.07 and a beta of 0.43. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.11. The business’s 50 day moving average is $57.39 and its 200 day moving average is $55.17.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.05%. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMY. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Bank of America reaffirmed a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Finally, BMO Capital Markets lifted their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.